ArticleMolecular biology reports2025
Investigation of expression levels of MIR125A and MIR126 genes in chronic obstructive lung disease.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-omics reveals a novel Cxcr4Clinical and translational medicine · 2026Article
- Evaluation of the impact of cardiopulmonary rehabilitation exercise training on cardiopulmonary function in patients with chronic obstructive pulmonary disease complicated by unstable angina pectoris using a hierarchical deep learning CT image model.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is a common lung disease characterized by airway inflammation, with high morbidity and mortality, and an increasing frequency with age. Small, non-coding RNA molecules known as microRNAs (miRNAs) control the expression of genes following transcription. In COPD, miR-125a-5p and miR-126-3p regulate disease progression; miR-125a-5p is usually low, linked to inflammation, while miR-126-3p varies. This study aims to examine their expression in COPD patients.
methodsThe expression levels of miR-125a-5p and miR-126-3p were measured using real-time polymerase chain reaction (RT-PCR) in a total of 52 healthy individuals and 53 patients diagnosed with COPD, including 16 with stable COPD and 37 experiencing acute exacerbations. Expression data of miRNAs were calculated by log2 - delta delta CT (2
resultsThe expression levels of miR-125a-5p were significantly lower and those of miR-126-3p significantly higher in COPD patients compared to controls (p = 0.045 and p = 0.034, respectively). However, when Acute COPD, Stable COPD, and Control groups were compared, no statistically significant differences were observed (p > 0.05).
conclusionIn this study, the expression level of miR-125a-5p was lower and miR-126-3p was higher in COPD patients compared to controls. However, no significant differences were observed among Acute, Stable, and Control groups.
Indexed as
Identifiers
41128976What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.